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INTRODUCTION
Neurofibromatosis type 1 (NF1) is a common autosomal
dominant genetic disorder with an incidence of approximate-
ly 1 in 3,000-3,500 individuals worldwide (1). NF1 is clin-
ically characterized by the presence of well established phe-
notypic features, including café-au-lait (CAL) spots, neurofi-
bromas, freckling of the axillary or inguinal region, Lisch nod-
ules, optic nerve gliomas, and bone dysplasias (1). Nearly all
NF1 patients have benign dermal neurofibromas, and approx-
imately 30% of NF1 patients have benign plexiform neurofi-
bromas which can undergo malignant transformation to
malignant peripheral nerve sheet tumors (MPNSTs) (2). Malig-
nant transformation into MPNSTs was observed in 2-13%
of NF1 patients with plexiform neurofibromas (3) and rep-
resents a major cause of mortality in NF1 patients (1).
Haploinsufficiency for neurofibromin has been suggested
as the molecular basis of the disease (1, 2). NF1 is caused by
mutations in 1 of the 2 alleles of the NF1 gene, located at
chromosome 17q11.2, encoding neurofibromin, a GTPase
activating protein (GAP). Approximately 5-20% of all NF1
patients have been reported to carry a heterozygous large ~1.5
Mb deletion at chromosome 17q11, where the entirety of the
NF1 gene and several neighboring genes exist, mediated by
homologous recombination between the NF1 repetitive
sequences (4). It has been reported that a bi-allelic inactiva-
tion of NF1, with one allele constitutionally inactivated and
the other somatically mutated, is required for neurofibroma
and MPNST formation (5), indicating that the tumor progres-
sion of NF1 is most likely triggered by the complete loss of
the NF1 gene in somatic cells. Somatic loss of heterozygosi-
ty (LOH) at the NF1 locus has been described for neurofibro-
mas and MPNSTs in previous studies (5). 
In a previous study, we reported the case of a 24-yr old male
NF1 patient with benign plexiform neurfiboromas and MPN-
STs (6). A whole gene expression comparison study was car-
ried out using tissue samples obtained by surgical resection
and skin biopsy from the patient. Because frequent genomic
imbalances in chromosomes 17, 19, and 22q in the neurofi-
bromas and MPNSTs have been reported in the patients with
NF1 (7), we also tested for genomic alterations and/or chro-
mosomal aberrations in the same patient in this study. Com-
parison study among normal, benign and malignant tissues
and cells was carried out on the chromosomal level. Here,
we report a Korean patient with NF1 who had a mosaic Y
chromosome loss involved in malignant progression. 
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Loss of Y Chromosome in the Malignant Peripheral Nerve Sheet
Tumor of a Patient with Neurofibromatosis Type 1
Neurofibromatosis type 1 (NF1) is one of the most commonly inherited autosomal
dominant disorders. In order to determine whether genomic alterations and/or chro-
mosomal aberrations involved in the malignant progression of NF1 were present
in a Korean patient with NF1, molecular and cytogenetic analyses were performed
on the pathologically normal, benign, and malignant tissues and primary cells cul-
tured from those tissues of the patient. The comparative genomic hybridization (CGH)
array revealed a Y chromosome loss in the malignant peripheral nerve sheet tumor
(MPNST) tissue. G-banding analysis of 50 metaphase cells showed normal chro-
mosomal patterns in the histopathologically normal and benign cultured cells, but
a mosaic Y chromosome loss in the malignant cells. The final karyotype for the malig-
nant cells from MPNST tissue was 45,X,-Y[28]/46,XY[22]. The data suggest that
the somatic Y chromosome loss may be involved in the transformation of benign
tumors to MPNSTs. 
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CASE REPORT
A 24-yr old male patient was diagnosed to have NF1 based
on standard diagnostic criteria at the Genetic Clinic in Ajou
University Hospital. The patient, having a NF1 nonsense
mutation (Y2264X) in the NF1 gene, preFsented the clini-
cal features of NF1 with café-au-Lait spots, plexiform neurofi-
bromas, cutaneous neurofibromas, subcutaneous neurofibro-
mas, scoliosis, and neurofibrosarcomas (MPNSTs) (6). After
surgical resection of tumors in the patient died at age of 25.
Tumor specimens containing benign and malignant tumors
and histopathologically normal tissues were obtained by sur-
gical resection and skin biopsy, respectively. Three types of
tissues, normal skin fibroblasts, benign plexiform neurofibro-
mas, and MPNSTs were prepared and histopathologically eval-
uated by routine light microscopy after staining with hema-
toxylin and eosin (H&E) as previously described (6).
To determine whether genomic alterations, including mic-
rodeletions and gene copy number changes, existed in this
male patient, we performed a comparative genomic hybri-
dization (CGH) array with high resolution CGH array slides
containing 1440 clones, including 356 cancer related genes
from BAC libraries at a resolution of 2.3 Mb. Three types of
tissues were used; normal skin fibroblasts, benign plexiform
neurofibromas, and malignant neurofibrosarcomas (MPNST),
all bearing an identical germ line mutation of the Y2264X
(c.6792C>G) nonsense mutation on the NF1 gene (6). 
DNA was extracted from the tissue samples and used for
a CGH array, performed as previously described (8). Com-
mercially available CGH array slides (Genomarray; Macro-
gen Inc., Korea) were analyzed using the chromofluor image
analysis system (Arrayscanner, Array analysis; Macrogen Inc.,
Korea). The slides contained 1440 clones from BAC libraries.
Each cloned BAC clone DNA was arrayed on the slide in
three spots. Non-NF1 male DNA was used as a reference.
The slides were scanned into two 16-bit TIFF image files
using GenePix4200A two-color fluorescent scanner (MDS
Inc., Canada) and quantitated using GenePix software (MDS
Inc., Canada). Green (reference) to red (test) (G/R) ratios were
automatically determined for each sample, and the normal-
ized G/R ratio was taken to represent the relative average num-
ber of copies of the sequence for those spots that were select-
ed as controls. Spots with G/R ratios more than the mean
plus 2.5 standard deviations (1.25) were considered as ampli-
fications or gains of the indicated copy number; less than the
mean minus 2.5 deviations (-0.75) were considered as losses
of the copy number. 
Control hybridization of non-NF1 male DNA was per-
formed in four independent experiments and resulted in a
mean log2 fluorescence ratio of 0.0±0.125 S.D., reflecting
the equal copy number in test and reference DNAs (data not
shown). Hybridization of non-NF1 male DNA (reference) vs.
DNA from normal tissue of the NF1 patient and further
hybridizations of DNA from normal tissue and from benign
or malignant tissues from the NF1 patient were performed
and their results shown in Fig. 1. Multiple tests were per-
formed to further narrow down the significant clones dis-
cussed in this paper. No genetic alteration, including DNA
copy number change across whole chromosomes, was detect-
ed in the hybridizations of reference DNA vs. DNA from
either normal tissue (Fig. 1A) or benign tissue (Fig. 1B). How-
ever, the loss of the whole Y chromosome was detected in the
hybridization of the DNA from normal tissue vs. the DNA
from MPNST tissue (Fig. 1C). The detailed CGH array pro-
file of the Y chromosome for NPNST tissue showed Y chro-
mosome-specific genomic loss across the whole region of the
Y chromosome (Fig. 1D). Therefore, we focused our study
on the Y chromosome aberrations in the MPNST tissue.
To confirm the CGH array findings, G-banding analysis
was performed on primary tissue cultured cells. First, primary
Fig. 1. CGH array profiles of the normal, benign and malignant
tissues of a patient with NF1. Graphics from the Macrogen’s Mac-
Viewer array CGH software show that CGH array profiles for whole
chromosomes by (A) hybridization of non-NF1 male DNA (refer-
ence) versus test DNA from normal tissue of the NF1 patient, (B)
hybridization of DNA from normal tissue versus DNA from benign
tissue of the NF1 patient, and (C) hybridization of DNA from nor-
mal tissue vs. DNA from MPNST tissue of the NF1 patient. Arrow
indicates where loss occurred in the Y chromosome. (D) Graphic
shows detailed CGH array profile for the whole region of Y chromo-
some in the hybridization of DNAs from normal tissues vs. MPNST
tissues of the NF1 patient. Two markers with a letter ‘C’ indicate
the position of centromere.
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tissue culture was performed by primary explant technique
from the pathologically normal, benign, and MPNST tissue
fragments. The dissected tissues were finely chopped, rinsed
with PBS, and the pieces were seeded onto the surface of a
culture T24 flask in a small volume (1 mL) of Dulbecco’s mod-
ified Eagle’s complete medium (DMEM) supplemented with
a high concentration (40%) of heat-treated fetal bovine serum
(FBS), 2 mM glutamine, non-essential amino acids, 2.5 mm
sodium pyruvate, 100 U/mL penicillin and 100 mg/mL strep-
tomycin. After an overnight incubation at 37℃, the medi-
um volume was made up to 5 mL and then changed weekly
until a substantial outgrowth of cells was observed. Cells were
then grown in DMEM media supplemented with 10% heat-
treated FBS.
Metaphase cells were harvested and G-banding analyses
were carried out using the cultured cells of 5 passages. Cyto-
genetic analyses were performed on GTG-banded metaphase
spreads prepared from three types of fibroblast cells from the
NF1 patient. The karyotypes were described in accordance
with ISCN (2009). Chromosome analyses were done in 50
metaphases for each sample with a resolution of 450 bands.
Representative GTG-banded karyotypes of 50 metaphases
are shown in Fig. 2. Normal karyotypes were observed in both
normal and benign tissue cultured cells (Fig. 2A), but abnor-
mal karyotype with a mosaic loss of the Y chromosome was
detected in the malignant tissue cultured cells (Fig. 2B). This
type of Y chromosome loss was detected in approximately 56%
of the counted cells (28/50). These G-banding study results
in primary tissue cultured cells reproduced the CGH array
findings in the same tissues. The karyotype for the malignant
cells from MPNST tissue revealed 45,X, -Y[28]/46, XY[22].
DISCUSSION
NF1 is notable for the malignant transformation of normal
and/or benign tumor tissues to malignant peripheral nerve
sheet tumors (MPNSTs) (3). Three different pathological phe-
notypes of tissues, normal, benign and malignant, may exist
within one individual despite of an identical germ line muta-
tion in the NF1 gene, supporting the two-hit hypothesis that
an additional NF1 loss is an independent, somatic event (9).
Studies on the somatic loss of heterozygosity (LOH) in NF1
showed that about 20% of dermal neurofibromas, 40% of
plexiform neurofibromas, and 60% of MPNSTs have a LOH
either at the NF1 locus or at 17q (5, 10). 
The molecular mechanisms potentially required for the full
transformation of benign neurofibromas into MPNSTs are
poorly understood. Loss of neurofibromin function by bi-allel-
ic inactivation of NF1 may be necessary for benign neurofi-
broma formation, but is not sufficient for the transformation
of neurofibromas to MPNSTs, suggesting that other genetic
alterations or epigenetic events must occur in benign tumors
for the malignant transformations in NF1 patients. At the gene
level, alterations like mutations and/or gene expression changes
in other genes including CDKN2A/p14
ARF/p15
INK4b/p16
INK4a,
CDKN1B/p27
KI11, RB, TP53, PTEN, EGFR, FRAP1
(mTOR), TSC2, TGF-b, HGF-a, TNXB, and TNC, have
been identified in MPNSTs (6, 11). In the chromosomal level,
several CGH studies of NF1-associated and sporadic MPNSTs
reported the existence of gains and/or losses of genetic mate-
rials in chromosomes, 4q, 7, 8q, 15q, 17p, 17q, 19, 22q, and
X (7, 12, 13). Although no previous studies have reported
common patterns of chromosomal aberrations in NF1, the
most frequent genomic imbalances in NF-1 associated MPN-
STs were detected in chromosome 17q (7). 
In our previous study, we reported the results of a gene
expression comparison study of a 24-yr old patient with NF1
(6). A whole gene expression comparison study was carried
out in normal, benign and malignant tissues and a total of 20
genes were identified showing clear differences in expression
patterns among those tissues. Recent studies regarding chro-
Fig. 2. GTG-banded karyotypes of the benign and malignant fibroblast cells from a NF1 patient. (A) Normal karyotype, 46,XY, was detect-
ed in metaphases of the benign cells. (B) Abnormal karyotype of loss of Y chromosome, 45,X,-Y, was detected in metaphases of the
malignant cells. Arrow indicates where loss occurred in the Y chromosome.  
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mosomal aberrations in NF1 led to this study in the chromo-
somal level of the same patient. Here, we performed molecu-
lar cytogenetic analysis using samples of the same normal,
benign and malignant tissues from the patient and also per-
formed cytogenetic analysis using the primary cultured cells
from those tissues. Initially, a comparison study was carried
out between tissue types using a CGH array. High-resolution
CGH arrays are a powerful tool for the detection of genomic
alterations, including gene copy number changes and chro-
mosome deletions and duplications (8). Recent studies have
identified a gain of a 550 kb segment at 7q, loss of 2.5 Mb at
17q11.2, and duplications in the NF1 locus at 17q11 through
CGH array analysis (14). Using a CGH array, we identified
the loss of the Y chromosome in the malignant tissue of a
patient with NF1. No genetic alterations were detected at the
NF1 locus on 17q. This result was supported by G-banding
analysis of cultured cells. Karyotype results showed a mosa-
ic loss in the Y chromosome of the malignant cells, but not
in the normal and benign cells, suggesting that the somatic
loss of the Y chromosome in this patient may be associated
with the malignant transformation of benign neurofibromas
to MPNSTs. In this study, Y chromosome loss was first detect-
ed through CGH array in MPNST tissue and confirmed by
cytogenetic analysis in cultured cells from MPNST tissue. This
ruled out the possibility that the Y chromosome loss occurred
during cell culture by chance.
Multiple studies have reported that loss of the Y chromo-
some is a normal age-related phenomenon (15). The likelihood
of Y chromosome loss increased significantly in normal males
after the age of 70. In our case study, the normal age-related
Y chromosome loss is less relevant as the NF1 patient is in his
mid-twenties. In addition, Y chromosome loss is frequently
observed in some types of tumors such as prostate cancer, pan-
creatic cancer, squamous cell carcinoma of the head and neck,
acute leukemia, hepatocellular carcinoma, and kaposi’s sar-
coma (16, 17). A study regarding the significance of Y chro-
mosome loss in hematologic diseases reported that the insti-
tutional incidence of Y chromosome loss was ~10% of hema-
tologic disease groups and the Y loss is frequently seen as
mosaicism with a normal (46,XY) clone (18). Our case had
a Y chromosome loss with mosaicism in 56% of the count-
ed cells. The molecular mechanisms of the loss of Y chromo-
some in these tumors remain unclear. Several cancer related
genes have been found to be located on the Y chromosome
at Yp, TSPY (Y-encoded testis-specific gene), Yq, XKRY (XK-
related protein on Y chromosome), PRY (PTPBL-related pro-
tein on Y), RRM (RNA recognition motif), YRRM2 (Y chro-
mosome RNA recognition motif 2), and CDY1 (Chromod-
omain on Y chromosome) (19). Although male predominance
has been reported in the NF1 patients with tibial pseudarthro-
sis (20), it is not clear whether these genes are associated with
malignant transformation of benign neurofibromas to MPN-
STs in this case. Further studies are necessary to elucidate the
relationship between Y chromosome-specific cancer related
genes and tumor progression of NF1.
To elucidate the mechanisms for the malignant transforma-
tion of NF1, we previously performed a comparison study at
the gene level in histopathologically different tissues of a Kore-
an patient with NF1 (6), and in the present study we carried
out comparison study on the genomic and chromosomal levels
in the same patient. As a result, we have found the mosaic
loss of the Y chromosome in MPNST tissues and cells of the
patient. This is the first reported case of Y chromosome loss
in NF1. Considering Y chromosome loss has been associat-
ed with some types of tumors (16, 17), this result strongly
suggests that the somatic loss of the Y chromosome may have
caused the transformation of benign tumors to MPNSTs in
this patient. Although we are reporting on one case, our data
may provide insight into improving the understanding the
underlying mechanisms of somatic tumor progression of NF1
on the chromosomal level. 
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